395 Results for "

tumor cell lines

" in MedChemExpress (MCE) Product Catalog:
Products (395)

395 Results for "tumor cell lines" in MCE Product Catalog:

46
46 Publications Verification
Cat. No.: HY-15205
CAS No.: 888216-25-9
Purity:  99.94%
Synonyms: STA-9090
Target:  

HSP Apoptosis

Research Areas:  

Cancer

Ganetespib (STA-9090) is a heat shock protein 90 (HSP90) inhibitor which exhibits potent cytotoxicity in a wide variety of hematological and solid tumor cell lines. Ganetespib has antiangiogenic effects in colorectal cancer mediated through inhibition of HIF-1α and STAT3 .
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-50909
CAS No.: 157716-52-4
Synonyms: KRX-0401; NSC 639966; D21266
Target:  

Akt Autophagy Apoptosis

Research Areas:  

Cancer

Perifosine is an oral Akt inhibitor which inhibits proliferation of different tumor cell lines with IC50s of 0.6-8.9 μM.
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-16261
CAS No.: 1361644-26-9
Synonyms: INNO-206; DOXO-EMCH
Research Areas:  

Cancer

Aldoxorubicin (INNO-206) is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-15096
CAS No.: 147366-41-4
Purity:  ≥98.0%
Synonyms: FJ-776
MKT-077 (FJ-776), a highly water-soluble mitochondrial dye, has significant antitumor activity . MKT-077 exhibits low cytotoxicity, and inhibits broad-spectrum human cancer cell lines (colon cancer, breast cancer, pancreatic cancer). MKT-077 inhibits the growth of tumor in nude mice enograft tumor model. Ex/Em=488/543 nm .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-100022
CAS No.: 1849590-01-7
Purity:  99.92%
Synonyms: eFT508
Target:  

MNK PD-1/PD-L1

Research Areas:  

Cancer

Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines . Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-13208
CAS No.: 1071992-57-8
Purity:  98.01%
Synonyms: AT-406 hydrochloride; Debio 1143 hydrochloride; SM-406 hydrochloride
Target:  

IAP Apoptosis

Research Areas:  

Cancer

Xevinapant (AT-406) hydrochloride is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). Xevinapant hydrochloride binds to XIAP, cIAP1, and cIAP2 proteins with Kis of 66.4, 1.9, and 5.1 nM, respectively. Xevinapant hydrochloride effectively antagonizes XIAP BIR3 protein in a cell-free functional assay, induces rapid degradation of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines. Xevinapant hydrochloride is highly effective in induction of apoptosis in xenograft tumors .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712
CAS No.: 1805833-75-3
Synonyms: CT7001; ICEC0942
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib has anti-tumor effects .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712A
CAS No.: 1805789-54-1
Purity:  99.90%
Synonyms: CT7001 hydrochloride; ICEC0942 hydrochloride
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712B
Purity:  99.06%
Synonyms: CT7001 hydrochloride dihydrate; ICEC0942 hydrochloride dihydrate
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103712C
Purity:  98.60%
Synonyms: CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-128586
CAS No.: 1848959-10-3
Purity:  99.52%
TAS4464 is a long-acting, highly selective covalent inhibitor targeting NEDD8-activating enzyme (NAE) (IC50=0.955 nM), and also inhibits CAII with an IC50 of 0.73 μM, which is less potent than MLN4924 (HY-70062). The IC50 values of TAS4464 against other E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively. TAS4464 targets NEDD8 in an ATP-dependent manner to inhibit NAE, blocks the neddylation pathway, causes accumulation of CRL ubiquitin ligase substrates (such as CDT1, p27, phosphorylated IκBα), and further induces tumor cell apoptosis. TAS4464 exhibits antiproliferative and cytotoxic effects, and has broad-spectrum antitumor activity against various hematologic and solid tumor cell lines as well as patient-derived tumor cells. TAS4464 has a wide selcetive window, without obvious toxicity. TAS4464 can be used in the research of hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer, etc.) .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-128586A
CAS No.: 1848959-11-4
Purity:  98.91%
TAS4464 hydrochloride is a long-acting, highly selective covalent inhibitor targeting NEDD8-activating enzyme (NAE) (IC50=0.955 nM), and also inhibits CAII with an IC50 of 0.73 μM, which is less potent than MLN4924 (HY-70062). The IC50 values of TAS4464 hydrochloride against other E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively. TAS4464 hydrochloride targets NEDD8 in an ATP-dependent manner to inhibit NAE, blocks the neddylation pathway, causes accumulation of CRL ubiquitin ligase substrates (such as CDT1, p27, phosphorylated IκBα), and further induces tumor cell apoptosis. TAS4464 hydrochloride exhibits antiproliferative and cytotoxic effects, and has broad-spectrum antitumor activity against various hematologic and solid tumor cell lines as well as patient-derived tumor cells. TAS4464 hydrochloride has a wide therapeutic window, without obvious toxicity. TAS4464 hydrochloride can be used in the research of hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer, etc.) .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-11005
CAS No.: 702674-56-4
Purity:  99.13%
Target:  

PDK-1 Apoptosis

Research Areas:  

Cancer

BX-912 is a direct, selective, and ATP-competitive PDK1 inhibitor (IC50=26 nM). BX-912 blocks PDK1/Akt signaling in tumor cells and inhibits the anchorage-dependent growth of a variety of tumor cell lines in culture or induces apoptosis .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-14807
CAS No.: 238750-77-1
Purity:  99.68%
Synonyms: CHR-2797
Target:  

Aminopeptidase

Research Areas:  

Cancer

Tosedostat (CHR-2797) is an orally active aminopeptidase inhibitor. CHR-2797 exerts antiproliferative effects against a range of tumor cell lines .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-12449
CAS No.: 1421438-81-4
Purity:  99.01%
Synonyms: LY3039478
Target:  

Notch γ-secretase

Research Areas:  

Cancer

Crenigacestat (LY3039478) is an orally active Notch and γ-secretase inhibitor, with an IC50 of 1 nM in most of the tumor cell lines tested .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-128587
CAS No.: 1816989-16-8
Purity:  98.02%
Synonyms: SY-1365
Target:  

CDK

Research Areas:  

Cancer

Mevociclib (SY-1365) is a potent and first-in-class selective CDK7 inhibitor, with a Ki of 17.4 nM. Mevociclib exhibits anti-proliferative and apoptotic effects in solid tumor cell lines. Mevociclib possesses anti-tumor activity in hematological and multiple aggressive solid tumors .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-145923
CAS No.: 2489404-97-7
Purity:  99.38%
Synonyms: ABBV-CLS-484
Target:  

Phosphatase STAT JAK

Research Areas:  

Cancer

Osunprotafib (ABBV-CLS-484) is an orally active and selective active site PTPN1 (IC50: 2.5 nM) and PTPN2(IC50: 1.8 nM) inhibitor. Osunprotafib has 6-8-fold weaker activity on PTPN9 and no detectable activity on SHP-1 or SHP-2. Osunprotafib increases the sensitivity of human cancer cell lines to IFNγ. Osunprotafib generates robust anti-tumor immunity by enhancing JAK-STAT signalling and reducing T cell dysfunction .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P99974
Synonyms: Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007

Research Areas:  

Cancer

Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11) .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-101667
CAS No.: 1879887-96-3
Purity:  99.35%
Target:  

DNA-PK

Research Areas:  

Cancer

LTURM34 is a specific DNA-PK inhibitor (IC50=34 nM). LTURM34 exhibits 170-fold selectivity for DNA-PK over PI3K. LTURM34 shows potent antiproliferative activity in a wide range of tumor cell lines .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-101849
CAS No.: 392721-37-8
Purity:  ≥98.0%
Research Areas:  

Cardiovascular Disease Cancer

Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .
loading...
    loading...